Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history

Human Vaccines

Volumn 6, Issue 10, 2010, Pages 829-834

  Larnaudie, S ^a   Guiso, N ^b   Baptiste, C ^c   Desaint, C ^d   Deforges, L ^e   Lebon, P ^f   Soubeyrand, B ^c   Launay, O ^d  

^a Service de Vaccination DASES Direction de l'Action Sociale de l'Enfance et de la Santé   (France)

^b CNRS   (France)

^c SANOFI PASTEUR   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f Institut Cochin   (France)

Author keywords

Adults; Combined vaccine; Diphtheria; Immunogenicity; Pertussis; Poliomyelitis; Tetanus

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; REVAXIS; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; ASTHENIA; BORDETELLA PERTUSSIS; CLOSTRIDIUM TETANI; CORYNEBACTERIUM DIPHTHERIAE; DEMOGRAPHY; DIARRHEA; DIPHTHERIA; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; FRANCE; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PAIN; PERTUSSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; SEROCONVERSION; TETANUS; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA TOXOID; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; FRANCE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; PERTUSSIS VACCINE; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINES; PROSPECTIVE STUDIES; TETANUS TOXOID; VACCINATION; VACCINES, COMBINED; YOUNG ADULT;

EID: 78649356216     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.10.12582     Document Type: Article

References (28)

1. Launay O, Toneatti C, Bernède C, Njamkepo E, Petitprez K, Leblond A, et al. Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations. Hum Vaccin 2009; 5:341-6.
2. Calendrier vaccinal 2009. BEH 2009; 17:145-76.
3. Scheifele DW, Ochnio JJ. The Immunological Basis for Immunization Series Module 2: Diphtheria Update 2009. Geneva: World Health Organisation 2009 [ISBN 978 92 4 159786 9].
4. Bonmarin I, Guiso N, Le Flèche-Matéos A, Patey O, Patrick AD, Levy-Bruhl D. Diphtheria: a zoonotic disease in France? Vaccine 2009; 27:4196-200.
5. World Health Organization. WHO vaccine-preventable diseases: monitoring system 2009 global summary. French reported cases. Accessed on 24 october 2009; at http://www.who.int/immunization-monitoring/en/globalsummary/timeseries/ TSincidenceByCountry.cfm?C=FRA.
6. World Health Organization. Weekly epidemiological record 2009; 84:109-16 available at http://www.who.int/wer/2009/wer8414.pdf.
7. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 2005; 24:10-8.
8. Bamberger ES, Srugo I. What is new in pertussis? Eur J Pediatr 2008; 167:133-9.
9. Wendelboe AM, Njamkepo E, Bourillon A, Floret DD, Gaudelus J, Gerber M, et al. Infant Pertussis Study Group. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293-9.
10. Scheifele DW, Halperin SA, Ochnio JJ, Ferguson AC, Skowronski DM. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 2005; 24:1059-66.
11. Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, et al. An adolescent-adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 2007; 25:1121-5. (Pubitemid 44937444)
12. Laroche P, Barrand M, Wood SC, Van Hasbrouck K, Lang J, Harzer E, et al. The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV). Infection 1999; 27:49-56.
13. Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003-11.
14. Southern J, Andrews N, Burrage M, Miller E. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 2005; 23:3829-35. (Pubitemid 40704747)
15. th at: http://www.fda.gov/OHRMS/DOCKETS/AC/05/ slides/2005-4097S1-06.ppt#256,1,Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap, ADACEL™) Aventis Pasteur, Ltd.
16. Borrow R, Balmer P, Roper MH. The Immunological Basis for Immunization Series Module 3: Tetanus Update 2006. Geneva: World Health Organisation 2007; [ISBN 978 924 159 555 1].
17. Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995; 754:289-99.
18. th ed. Philadelphia, PA: WB Saunders Company 2004; 471-528.
19. Taranger J, Trollfors B, Bergfors E, Knutsson N, Lagergård T, Schneerson R, et al. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics 2001; 108:115.
20. Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergård T, et al. Mass vaccination of children with pertussis toxoid - decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001; 33:1004-10.
21. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003; 21:3542-9.
22. Theeten H, Rümke H, Hoppener FJ, Vilatimó R, Narejos S, Van Damme P, et al. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin 2007; 23:2729-39. (Pubitemid 350146410)
23. Siegrist CA. [Vaccinology: which catch-up plans for patients with unknown or incomplete immunizations?]. Rev Med Suisse 2009; 5:63-8.
24. Salk D,Van Wezel AL, Salk J. Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. The Lancet 1984; 1317-21.
25. Guerin N, Fillastre C, Lanel V, Ajjan N. Evaluation de l'immunité diphtérique chez les enfants. Le Pédiatre 1988; 109:77-80.
26. OMS. Les bases immunologiques de la vaccination, le tétanos. WHO/EPI/GEN/93.13.
27. Meade B, Deforest A, Edwards KM, Romani TA, Lynn F, O'Brien CH, et al. Description and evaluation of serologic assays used in a multicenter trial on acellular pertussis vaccines. Pediatrics 1995; 96:570-5.
28. Richardson G, Linkins RW, Eames MA, Wood DJ, Campbell PJ, Ankers E, et al. Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes. Bull World Health Organ 1995; 73:769-77. (Pubitemid 26483698)